Long‐term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors. Issue 18 (25th July 2022)

• Record Type: Journal Article
• Authors: Lu, Zhenxing; Teng, Yintong; Ning, Xiaodong; Wang, Hao; Feng, Weijing; Ou, Caiwen
• Is Part Of: Cancer. Volume 128:Issue 18(2022)
• Page Start: 3330
• Page End: 3339
• Publication Date: 2022-07-25
• Subjects: cardiovascular disease -- classic Hodgkin lymphoma -- mortality -- SEER -- temporal trend; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.34375
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Background: The temporal trend of cardiovascular disease (CVD) mortality in patients with classic Hodgkin lymphoma (cHL) throughout follow‐up remains unclear. This study aimed to assess this temporal trend in patients with cHL. Methods: This multicenter cohort included 15, 889 patients with cHL diagnosed between 1983 and 2015, covering all ages. The proportional mortality ratio, cumulative incidence of cause‐specific mortality accounting for competing risk, standard mortality ratio, and absolute excess risk were analyzed. Results: Among patients in stage I and stage II cHL, the proportional mortality ratio for CVD exceeded that for cHL, after approximately 60 or 120 months of follow‐up, respectively. For almost all the patients with stage I or stage II disease, the cumulative incidence of CVD mortality exceeded that of cHL and other neoplasms over time. In recent decades, the risk of cHL mortality declined sharply, but the risk of CVD mortality among patients with cHL declined quite slowly or even remained unchanged among some populations. Patients with stage I or stage II disease experienced a higher risk of CVD mortality than the general population in almost all follow‐up intervals. The absolute excess CVD risk among patients in stage I reached 48.5. Conclusions: The risk of CVD mortality exceeded that of cHL and other neoplasms and became the leading cause of death over time, among patients with stage I or stage II disease. More effective measures should be taken to reduce the risk of CVD mortality. Lay summary: Among patients with stage I and stage II classic Hodgkin lymphoma (cHL), the proportional mortality ratio of cardiovascular disease (CVD) exceeded that of cHL after approximately 60 or 120 months of follow‐up, respectively. For almost all the patients with stage I or stage II disease, the cumulative incidence of CVD mortality exceeded that of cHL and other neoplasms over time. In the past several decades, the risk of cHL mortality declined sharply, but the risk of CVD mortality among patients with cHL declined quite slowly or even unchanged among some populations. CVD exceeded cHL and has become the leading cause of death over time. Abstract : The risk of cardiovascular disease (CVD) mortality exceeded that of classic Hodgkin lymphoma (cHL) and other neoplasms and became the leading cause of death over time among patients with stage I or stage II disease. In the past several decades, the risk of CVD mortality among patients with cHL declined quite slowly, which was not as expected.